We greatly appreciate the thoughtful comments in regards to our manuscript, which
highlight a number of important issues about the use of PSMA-PET. It should be noted
at the outset that PSMA-PET should not be considered a standard imaging modality.
In the United States, PSMA-PET is investigational and is not FDA approved. Although
PSMA-PET may be considered standard of care in a few countries, its use in the United
States is limited to clinical trials. Nonetheless, the prevalence of PSMA-PET is likely
to increase in the next few years, as we should be close to approval of this agent
in the coming year. Our hope is that the preliminary data presented in our manuscript
may help guide the use of PSMA-PET imaging.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.BJU International. 2017; 119: 209-215https://doi.org/10.1111/bju.13540
- 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.European Urology. 2016; 70: 553-557https://doi.org/10.1016/j.eururo.2015.12.051
- Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer.J Transl Med. 2017; 15: 230https://doi.org/10.1186/s12967-017-1333-2
- Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.European Urology. 2016; 69: 393-396https://doi.org/10.1016/j.eururo.2015.06.010
- Predicting the Risk of Pelvic Node Involvement Among Men With Prostate Cancer in the Contemporary Era.Int J Radiat Oncol Biol Phys. 2009; 74: 104-109https://doi.org/10.1016/j.ijrobp.2008.07.053
- External Validation of Models Predicting the Probability of Lymph Node Involvement in Prostate Cancer Patients.European Urology Oncology. 2018; 1: 411-417https://doi.org/10.1016/j.euo.2018.04.016
Article info
Identification
Copyright
© 2018 Published by Elsevier Inc.
